Effects of nicorandil as compared to mixtures of sodium nitroprusside and levcromakalim in isolated rat aorta.
1. The contribution of the relaxant mechanisms of nicorandil (NIC) were analysed by comparing its effects with those of sodium nitroprusside (SNP), levcromakalim (LEM) and mixtures (1:10, 1:30 and 1:100) of SNP:LEM in isolated endothelium-denuded rat aorta. 2. In rings precontracted with KCl (25 mM), the relative inhibitory potency of the soluble guanylate cyclase inhibitor ODQ and the K(ATP) channel inhibitor glibenclamide (GLI) on SNP:LEM mixtures showed a good correlation with the relative proportion of SNP and LEM in the mixtures. Furthermore, the degree of the inhibition by ODQ and GLI of the effects of the 1:30 SNP:LEM mixture varied as a function of the relative potency of SNP and LEM in KCl-, noradrenaline- (NA) or NA plus nifedipine-treated arteries. 3. The inhibitory effects of ODQ, GLI and ODQ plus GLI on NIC-induced relaxation was similar to that for the 1:30 SNP:LEM mixture in NA plus nifedipine-contracted arteries, but the inhibition of GLI or ODQ plus GLI was smaller in KCl-contracted arteries. 4. In conclusion, the relative importance of activation of the cyclic GMP pathway and K(ATP) channel opening in mixtures of SNP and LEM could be predicted by the proportion of the drugs in the mixtures and by the relative potency of SNP vs LEM in different experimental conditions. Furthermore, the present results suggest that besides these two mechanisms, a third ODQ- and GLI-insensitive mechanism, possibly involving Ca2+ channel blockade, also participates in the relaxant effects of NIC in KCl-induced contractions.
Cogolludo
A L
AL
Departamento de Farmacología, Instituto de Farmacología y Toxicología (CSIC), Facultad de Medicina, Universidad Complutense de Madrid, Spain.
Pérez-Vizcaíno
F
F
Fajardo
S
S
Ibarra
M
M
Tamargo
J
J
D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000502:physiology; D019806:Cromakalim / Q000494:pharmacology*; D006152:Cyclic GMP / Q000502:physiology; D005905:Glyburide / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D020108:Nicorandil / Q000494:pharmacology*; D009599:Nitroprusside / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014661:Vasoconstriction; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D019806:Cromakalim; D009599:Nitroprusside; D020108:Nicorandil; D011189:Potassium Chloride; D006152:Cyclic GMP; D005905:Glyburide; D009638:Norepinephrine